



## **Medical Compression System (D.B.N.) Ltd.**

March 2, 2008

Israel Securities Authority  
via MAGNA

Tel Aviv Stock Exchange Ltd.  
via MAGNA

re: **Execution of agreements for the provision of 550 devices to Scripps Mercy SD and Scripps Green Hospitals**

To whom it may concern,

The Company respectfully announces that on February 29, 2008, it received an order from Scripps Mercy San Diego Hospital for 400 of the company's devices for the prevention of DVT and an order from Scripps Green Hospital for the provision of 150 said devices (total of 550 devices). Said orders are in addition to the 250 devices ordered by Scripps Memorial Hospital, as reported by the Company on January 13, 2008, 130 devices ordered by Scripps Encinitas Hospital, as reported by the Company on February 20, 2008 and 100 devices ordered by Scripps Mercy Chula Vista Hospital, as reported by the Company on February 27, 2008.

Said orders complete the transition of all five Scripps hospitals, a leading network of hospitals in Southern California, to use of the Company's devices for the prevention of DVT. The provision of the devices and associated disposable accessories (sleeves) is done directly between the Company and the network's hospitals, unlike in other cases in which the devices and associated disposable accessories (sleeves) are provided by the Company's distributor in the US. Said order of the devices is attributable to the hospitals' decision to begin using the Company's devices for the prevention of DVT instead of Kendall's (a competitor) devices, which the Scripps network hospitals had used to date.

The Company expects revenues from Scripps Mercy San Diego and Scripps Green hospitals to amount to approximately \$700,000 annually.

In total, the Company will provide the Scripps network with 1,030 devices, and the projected revenue from all network hospitals is approximately \$1.3 million annually.

It should be noted that said replacement of the devices in the hospitals is to use the Company's devices instead of the competitor's, and does not constitute the selection of use of the devices instead of the leading medication. As aforementioned in the Company's previous reports, the

**Medical Compression Systems (D.B.N) Ltd, 2 Ha'Ilan St, Or Akive, 30600**  
**Tel: +972-4-626-6630, Fax: +972-4-626-6640**  
**[www.mcsmed.com](http://www.mcsmed.com)**



Company's product is in a clinical trial, in which it is being tested against the leading medication for prevention of DVT.

Company estimates regarding the projected revenues from the hospitals are forward-looking statements, as defined in the Securities Law, and there is no guarantee that said statements will materialize. The Company's estimates are based on its familiarity with the relevant hospitals and its estimates regarding the volume of their activity. These estimates may not materialize, in whole or in part, or materialize materially differently than expected, and this for various reasons, including a different volume of activity than expected at the hospitals in the network and more.

Sincerely,

Medical Compression System (D.B.N.) Ltd.